New Limit
4 known investors
NewLimit develops epigenetic reprogramming medicines to extend healthspan and treat age-related diseases at the intersection of computer science and biotechnology. The company builds therapeutic programs that aim to engineer cell identity and reprogram cell age for human patients.
Founders & leadership
J
JacobCo-founder, Head of Research, President, and CEO
BA
Brian ArmstrongCo-founder, Board of Directors